David J. Woodhouse is CEO at NGM BIOPHARMACEUTICALS INC (NGM). They have made 1 open-market trade across 1 company since 2021, most recently 2024-04-05.
CIK 0001642995
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NGM | 131,822 | $203K |
Shares reported on the most recent Form 4, priced at the 2024-01-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NGM | SELL | 2021-11-18 | 2021-11-19 | $20.02 | $300K | -5.8% | -8.4% | -21.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.